In addition to eGFP reporter‐based studies, we assessed the efficacy of AAV2.GL in a preclinical proof‐of‐concept study for intravitreal gene supplementation in degenerating cones of the Cnga3−/− mouse model of achromatopsia. This evidence concerns the gene CNGA3 and achromatopsia.